AI assistant
Sending…
Oncopeptides — Major Shareholding Notification 2024
Jun 3, 2024
3091_iss_2024-06-03_3a164e22-767f-485a-8438-1a7b2b886178.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer Oncopeptides AB
Holder
Stiftelsen Industrifonden
Instrument
| Instrument | Ordinary Shares | |
|---|---|---|
| Before the transaction | ||
| Shares | 8,285,258 | |
| Voting rights | 8,285,258 | |
| Transaction | ||
| Reason for major shareholding notification Corporate action | ||
| Date | 31/05/2024 | |
| Limit for number of shares | 5 % | |
| Limit for number of votes | 5 % | |
| After the transaction | ||
| Quantity | ||
| Shares | 8,285,258 | |
| Directly held voting rights | 8,285,258 | |
| Indirectly held voting rights | 0 | |
| Percentage | ||
| Directly held shares | 3.85027 % | |
| Directly held voting rights | 3.91846 % | |
| Indirectly held voting rights | 0 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 3.91846 % | 8,285,258 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled - Cash settled |
||
| Total | 3.91846 % | 8,285,258 |
| Group total holdings Voting rights 8,285,258 Percentage of voting rights 3.91846 |
||
| Notes (other relevant informations according to law) Changes due to: Corporate action, Rights issue |
||
| Published 03/06/2024 09:30 |
||
| Contact | ||
| Name Caroline Murray |

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Interim / Quarterly Report
2026
May 13
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 28
Major Shareholding Notification
2026
Apr 24
Major Shareholding Notification
2026
Apr 21
Proxy Solicitation & Information Statement
2026
Apr 16